Anbeixin®Enalapril Maleate Oral Solution

Biokin pediatric drugs family added a new member once again. On June 28, 2022, Anbeixin®Enalapril Maleate Oral Solution was approved by NMPA, bringing a more precise,  convenient therapy option for the child patients with hypertension, cardiac failure and kidney disease at all ages.

R&D Project Encouraged by the State

l         Funded by National Critical New Medicines Creation Special Projects

l         Grant in the List of the Third Batch of Pediatric Drugs Encouraged for R&D and Application

Solution Dose Form with Strawberry Taste

l         1mg/ml, with precise dosage 

l         Strawberry taste, one time per day, with better compliance of child patients

Anbeixin for Children

Biokin Pharmaceuticals has always devoted to the field of pediatric drugs. In addition to Anbeixin, there are seven products with grants in National Critical New Medicines Creation Special Projects in the pre-marketing phase on the R&D pipeline of our pediatric drug family, involving pediatric severe illness, perioperative period and neurosurgery and other therapeutic areas; and the innovative drug projects focusing on the field of hematological tumors are also expected to enter the clinical trial phase of pediatric drugs in the second half of this year.